Crossmark

A phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction

Crossref DOI link: https://doi.org/10.1007/s10147-020-01638-5

Published Online: 2020-03-02

Published Print: 2020-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hosoda, Kei https://orcid.org/0000-0002-9787-2889
Azuma, Mizutomo

Katada, Chikatoshi

Ishido, Kenji

Niihara, Masahiro

Ushiku, Hideki

Sakuraya, Mikiko

Washio, Marie

Wada, Takuya

Watanabe, Akinori

Harada, Hiroki

Tanabe, Satoshi

Koizumi, Wasaburo

Yamashita, Keishi

Hiki, Naoki
License Information

Text and Data Mining valid from 2020-03-02

Version of Record valid from 2020-03-02
More Information

Article History

Received: 15 August 2019

Accepted: 20 February 2020

First Online: 2 March 2020

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below